Search results for: L. Adisso

Authors: A. A. Njoh, S. T. Ndoula, A. Adidja, G. N. Menan, A. Mengue, E. Mboke, H. B. Bachir, S. C. Nchinjoh, L. Adisso, Y. Saidu, L. Cleenewerck de Kiev

Abstract:

Vaccines serve a great deal in protecting the population globally. Vaccine products are subject to rigorous quality control and approval before use to ensure safety. Even if all actors take the required precautions, some people could still have adverse events following immunization (AEFI) caused by the vaccine composition or an error in its administration. AEFI underreporting is pronounced in low-income settings like Cameroon. The Country introduced electronic platforms to strengthen surveillance. With the introduction of many novel vaccines, like COVID-19 and the novel Oral Polio Vaccine (nOPV) 2, there was a need to monitor AEFI in Cameroon. A cross-sectional study was conducted from July to December 2022. Data on AEFI per region of Cameroon were reviewed for the previous five years. Data were analyzed with MS Excel, and the results were presented in proportions. AEFI reporting was uncommon in Cameroon. With the introduction of novel vaccines in 2021, the health authorities engaged in new tools and training to capture cases. AEFI detected almost doubled using the open data kit (ODK) compared to previous platforms, especially following the introduction of the nOPV2 and COVID-19 vaccines. The AEFI rate was 1.9 and 160 per administered 100,000 doses of nOPV2 and COVID-19 vaccines, respectively. This mobile tool captured individual information for people with AEFI from all regions. The platform helped to identify common AEFI following the use of these new vaccines. The ODK mobile technology was vital in improving AEFI reporting and providing data to monitor the use of new vaccines in Cameroon.

Keywords: Adverse events following immunization, AEFI, Cameroon, COVID-19 vaccines, novel oral polio vaccine 2, open data kit.

Procedia APA BibTeX Chicago EndNote Harvard JSON MLA RIS XML ISO 690 PDF Downloads 171